$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

$alxo Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023007013 Filed on March 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.440M	$7.022M	$29.04M
YoY Change	-3.05%	-7.34%	24.17%
% of Gross Profit
Research & Development	$24.76M	$25.20M	$98.40M
YoY Change	45.04%	20.59%	63.54%
% of Gross Profit
Depreciation & Amortization	$213.0K	$105.0K	$342.0K
YoY Change	267.24%	208.82%	570.59%
% of Gross Profit
Operating Expenses	$32.20M	$32.22M	$127.4M
YoY Change	30.13%	13.16%	52.52%
Operating Profit	-$32.20M		-$127.4M
YoY Change	30.13%		52.52%
Interest Expense	$387.0K	$1.807M	$4.278M
YoY Change	72.0%	-60333.33%	-33007.69%
% of Operating Profit
Other Income/Expense, Net	$95.00K	-$233.0K	-$260.0K
YoY Change	-963.64%	-1556.25%	-409.52%
Pretax Income	-$30.18M	-$30.65M	-$123.4M
YoY Change	23.03%	7.68%	47.83%
Income Tax		$64.00K	$64.00K
% Of Pretax Income
Net Earnings	-$30.18M	-$30.71M	-$123.5M
YoY Change	23.03%	7.99%	47.95%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.74		-$3.03
Diluted Earnings Per Share	-$0.74	-$0.75	-$3.03
COMMON SHARES
Basic Shares Outstanding	40.86M	40.76M	40.70M
Diluted Shares Outstanding	40.86M		40.70M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$227.9M	$266.2M	$266.2M
YoY Change	-28.0%	-26.8%	-26.8%
Cash & Equivalents	$63.19M	$48.82M	$48.82M
Short-Term Investments	$164.8M	$217.4M	$217.4M
Other Short-Term Assets	$4.592M	$4.762M	$4.762M
YoY Change	-6.84%	42.06%	42.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$232.5M	$271.0M	$271.0M
YoY Change	-27.68%	-26.17%	-26.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.932M	$3.889M	$9.789M
YoY Change	193.87%	333.56%	188.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$28.22M	$16.70M	$16.70M
YoY Change	12.39%
Other Assets	$13.45M	$14.93M	$9.032M
YoY Change	-14.35%	21.72%	-7.53%
Total Long-Term Assets	$45.60M	$35.52M	$35.52M
YoY Change	8.19%	169.83%	169.83%
TOTAL ASSETS
Total Short-Term Assets	$232.5M	$271.0M	$271.0M
Total Long-Term Assets	$45.60M	$35.52M	$35.52M
Total Assets	$278.1M	$306.5M	$306.5M
YoY Change	-23.52%	-19.38%	-19.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.826M	$8.073M	$8.073M
YoY Change	91.43%	114.48%	114.48%
Accrued Expenses	$11.63M	$19.79M	$19.79M
YoY Change	19.31%	78.27%	78.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$286.0K
YoY Change	-100.0%	-100.0%	-33.33%
Total Short-Term Liabilities	$21.89M	$28.33M	$28.33M
YoY Change	43.0%	85.19%	85.19%
LONG-TERM LIABILITIES
Long-Term Debt	$9.450M	$9.389M	$9.389M
YoY Change	5300.0%	3253.21%	3253.21%
Other Long-Term Liabilities	$6.409M	$5.311M	$5.311M
YoY Change	34.3%	188.8%	240.67%
Total Long-Term Liabilities	$15.86M	$14.70M	$14.70M
YoY Change	232.33%	699.35%	699.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.89M	$28.33M	$28.33M
Total Long-Term Liabilities	$15.86M	$14.70M	$14.70M
Total Liabilities	$37.75M	$43.03M	$43.03M
YoY Change	88.0%	151.11%	151.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$355.7M	-$325.5M
YoY Change	57.01%	61.13%
Common Stock	$596.1M	$589.8M
YoY Change	4.45%	4.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$240.4M	$263.5M	$263.5M
YoY Change
Total Liabilities & Shareholders Equity	$278.1M	$306.5M	$306.5M
YoY Change	-23.52%	-19.38%	-19.38%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$30.18M	-$30.71M	-$123.5M
YoY Change	23.03%	7.99%	47.95%
Depreciation, Depletion And Amortization	$213.0K	$105.0K	$342.0K
YoY Change	267.24%	208.82%	570.59%
Cash From Operating Activities	-$27.82M	-$20.67M	-$89.22M
YoY Change	34.55%	18.18%	31.02%
INVESTING ACTIVITIES
Capital Expenditures	$690.0K	$389.0K	$1.427M
YoY Change	17.15%	-108.61%	114.26%
Acquisitions
YoY Change
Other Investing Activities	$42.99M	$11.33M	-$234.0M
YoY Change	-123.45%
Cash From Investing Activities	$42.30M	$10.94M	-$235.4M
YoY Change	-123.0%	-342.19%	4681.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-107.0K	9.494M	9.860M
YoY Change	-233.75%	1711.83%	298.87%
NET CHANGE
Cash From Operating Activities	-27.82M	-20.67M	-89.22M
Cash From Investing Activities	42.30M	10.94M	-235.4M
Cash From Financing Activities	-107.0K	9.494M	9.860M
Net Change In Cash	14.37M	-232.0K	-314.8M
YoY Change	-107.03%	-98.92%	346.17%
FREE CASH FLOW
Cash From Operating Activities	-$27.82M	-$20.67M	-$89.22M
Capital Expenditures	$690.0K	$389.0K	$1.427M
Free Cash Flow	-$28.51M	-$21.06M	-$90.65M
YoY Change	34.06%	62.35%	31.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001810182
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.151961827
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39386
CY2022	dei	Entity Registrant Name EntityRegistrantName	ALX ONCOLOGY HOLDINGS INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0642577
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	323 Allerton Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	466-7125
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	ALXO
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	172600000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40863049
CY2022	dei	Auditor Location AuditorLocation	San Francisco, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48822000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	363667000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	217385000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4762000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3352000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	270969000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	367019000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3889000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	16699000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14932000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12267000
CY2022Q4	us-gaap	Assets Assets	306489000
CY2021Q4	us-gaap	Assets Assets	380183000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8073000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3764000
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1650000
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1630000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18602000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9901000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28325000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15295000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9389000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5311000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1839000
CY2022Q4	us-gaap	Liabilities Liabilities	43025000
CY2021Q4	us-gaap	Liabilities Liabilities	17134000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40861386
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40861386
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40587067
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40587067
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589735000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	564993000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-845000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-325467000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201985000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	263464000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	363049000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	306489000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	380183000
CY2022	alxo	Type Of Revenue Description TypeOfRevenueDescription	Related-party revenue
CY2021	alxo	Type Of Revenue Description TypeOfRevenueDescription	Related-party revenue
CY2020	alxo	Type Of Revenue Description TypeOfRevenueDescription	Related-party revenue
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1182000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	98400000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60170000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28961000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29036000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23385000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14809000
CY2020	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1075000
CY2022	us-gaap	Operating Expenses OperatingExpenses	127436000
CY2021	us-gaap	Operating Expenses OperatingExpenses	83555000
CY2020	us-gaap	Operating Expenses OperatingExpenses	44845000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-127436000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-83555000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-43663000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4278000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	91000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	124000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-260000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1339000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-123418000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83484000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45499000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123482000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5202000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-123482000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83463000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50942000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.03
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.03
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.07
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.07
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.76
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.76
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40699612
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40699612
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40308050
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40308050
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18485343
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18485343
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123482000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5202000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-123482000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83463000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50942000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-845000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-124327000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83463000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50942000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-70639000
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	1019000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	175043000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	364400000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	299000
CY2020	alxo	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	27000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5436000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	429845000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2551000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	202000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13914000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	363049000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	567000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	336000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23839000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-845000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123482000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	263464000
CY2022	us-gaap	Profit Loss ProfitLoss	-123482000
CY2021	us-gaap	Profit Loss ProfitLoss	-83463000
CY2020	us-gaap	Profit Loss ProfitLoss	-45740000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	342000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	202000
CY2022	alxo	Operating Finance Lease Right Of Use Asset Amortization Expense OperatingFinanceLeaseRightOfUseAssetAmortizationExpense	1124000
CY2021	alxo	Operating Finance Lease Right Of Use Asset Amortization Expense OperatingFinanceLeaseRightOfUseAssetAmortizationExpense	685000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4739000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	23839000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	13914000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5436000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	940000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	44000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	421000
CY2020	alxo	Changes In Fair Value Of Compound Derivative Liability And Warrants ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants	650000
CY2020	alxo	Gain On Assignment Of Lease GainOnAssignmentOfLease	126000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000
CY2020	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-536000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1476000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1662000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1514000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-750000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9682000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4506000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3290000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3744000
CY2022	alxo	Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent	20000
CY2021	alxo	Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent	1419000
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7027000
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3306000
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4983000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-977000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-698000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89223000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68101000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38289000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	376789000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	142800000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1427000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	666000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4257000
CY2020	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	641000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-235416000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4923000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	610000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	368256000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3848000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	567000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2551000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	299000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	336000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	202000
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	104680000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	388000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	281000
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	655000
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	6506000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9860000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2472000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	462881000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-314779000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-70552000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	425202000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363667000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	434219000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9017000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48888000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363667000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	434219000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	103000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	11000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	427000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	274000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	47000
CY2020	alxo	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	27000
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2145000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	237000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	7000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	482000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	175043000
CY2020	alxo	Non Cash Accumulated Dividend On Convertible Preferred Stock NonCashAccumulatedDividendOnConvertiblePreferredStock	3000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4613000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1780000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	776000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48822000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	363667000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	434219000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	66000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48888000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363667000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	434219000
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Certain reclassifications have also been made within the consolidated statements of operations for the years ended December 31, 2021 and 2020 to conform to the current year presentation. For the year ended December 31, 2021, the Company reclassified approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million out of other income (expense), net into a separate interest income financial statement line item as well as combined a nominal amount of interest expense into other income (expense), net, which is now renamed other expense, net. For the year ended December 31, 2020, the Company reclassified approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million out of other income (expense), net into a separate interest income financial statement line item as well as combined approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million amount of interest expense into other income (expense), net, which is now renamed other expense, net. Total loss before income taxes as of December 31, 2021 and 2020 did not change as a result of these reclassifications.</span></p>
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 8, 2020, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, fair value of investments, valuation of the Company’s common stock in periods prior to its initial public offering and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3889000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5626000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1829000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	298000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	746000
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	144000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4292000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	960000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	403000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	274258000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	357181000
CY2022Q4	us-gaap	Cash Cash	8600000
CY2021Q4	us-gaap	Cash Cash	6500000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	257559000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	357181000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	16699000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	274258000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	357181000
CY2022	alxo	Fair Value Assets And Liabilities Transfers Amount FairValueAssetsAndLiabilitiesTransfersAmount	0
CY2021	alxo	Fair Value Assets And Liabilities Transfers Amount FairValueAssetsAndLiabilitiesTransfersAmount	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1000000.0
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	144000
CY2022Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	78000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	66000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14932000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12267000
CY2022Q4	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	5485000
CY2021Q4	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	4119000
CY2022Q4	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	5249000
CY2021Q4	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	693000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3708000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3294000
CY2022Q4	alxo	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	2110000
CY2021Q4	alxo	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	27000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	835000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	790000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	755000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	286000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	429000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	174000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	236000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18602000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9901000
CY2022	us-gaap	Lessee Finance Lease Option To Extend LesseeFinanceLeaseOptionToExtend	no
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5600000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	300000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	700000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	1240000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due In Next Rolling Twelve Months FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths	288000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	1267000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	1305000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	1187000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	912000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	2069000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7980000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	288000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1957000
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6023000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	286000
CY2022Q4	alxo	Operating Lease Liability Current Including Payable And Accrued Liabilities Due To Related Party OperatingLeaseLiabilityCurrentIncludingPayableAndAccruedLiabilitiesDueToRelatedParty	765000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	286000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5258000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6023000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	286000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.017
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1159000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	360000
CY2022	alxo	Variable Lease Cost And Other Net VariableLeaseCostAndOtherNet	262000
CY2021	alxo	Variable Lease Cost And Other Net VariableLeaseCostAndOtherNet	84000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	88000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	447000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	369000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000
CY2022	us-gaap	Lease Cost LeaseCost	1965000
CY2021	us-gaap	Lease Cost LeaseCost	826000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	933000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	243000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	8000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	388000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	281000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4613000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1780000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	776000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5128639
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.91
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	49745000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1481234
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.89
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	171838
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	435000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5217000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	4948000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	10600000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q4	alxo	Term Loan Non Current TermLoanNonCurrent	10600000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	993000
CY2022Q4	alxo	Term Loan Unamortized Final Payment TermLoanUnamortizedFinalPayment	-218000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9389000
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40861386
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40587067
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11097469
CY2022	alxo	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.30
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	241187
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	44.58
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6196848
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.56
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19872000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3663358
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.73
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	18824000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	48100000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4400000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.008
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.819
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.847
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.797
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.869
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.787
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.890
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.29
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.74
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25918000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17532000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9555000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23839000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13914000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5436000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	52400000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-111360000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-30565000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9457000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12058000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-52919000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-36042000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-123418000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83484000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45499000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	64000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-21000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	64000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	241000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2659000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-105000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3098000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2368000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4031000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1779000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2131000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	512000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9067000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11476000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5710000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	36000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	172000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	321000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	18949000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	11032000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	7380000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1098000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16319000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15407000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8435000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5325000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000
CY2022Q4	alxo	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	1860000
CY2021Q4	alxo	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	529000
CY2022Q4	alxo	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	3860000
CY2021Q4	alxo	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	1530000
CY2022Q4	alxo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	1323000
CY2021Q4	alxo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	542000
CY2022Q4	alxo	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	1702000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33513000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23349000
CY2022Q4	alxo	Deferred Tax Liabilities Property Plant And Equipment1 DeferredTaxLiabilitiesPropertyPlantAndEquipment1	215000
CY2021Q4	alxo	Deferred Tax Liabilities Property Plant And Equipment1 DeferredTaxLiabilitiesPropertyPlantAndEquipment1	73000
CY2022Q4	alxo	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	1244000
CY2021Q4	alxo	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	541000
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	252000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1711000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	614000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31802000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22735000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9100000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1200000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1217000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	842000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	692000
CY2022	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	13000
CY2021	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-69000
CY2020	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-64000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	443000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	494000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	240000
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	12000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	50000
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	26000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1661000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1217000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	842000
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123482000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	5202000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-123482000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83463000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50942000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40699612
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40699612
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40308050
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40308050
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18485343
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18485343
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7017174
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5143714
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4857371
CY2022Q4	alxo	Number Of Pending Or Threatened Litigation NumberOfPendingOrThreatenedLitigation	0
CY2021Q4	alxo	Number Of Pending Or Threatened Litigation NumberOfPendingOrThreatenedLitigation	0
CY2020Q4	alxo	Number Of Pending Or Threatened Litigation NumberOfPendingOrThreatenedLitigation	0
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	10953000
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	9590000
CY2022Q4	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	1323000
CY2022Q4	us-gaap	Purchase Obligation Due In Fourth And Fifth Year PurchaseObligationDueInFourthAndFifthYear	40000
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	10953000
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	9590000
CY2022Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	1323000
CY2022Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	40000
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0000950170-23-007013-index-headers.html	Edgar Link	pending
0000950170-23-007013-index.html	Edgar Link	pending
0000950170-23-007013.txt	Edgar Link	pending
0000950170-23-007013-xbrl.zip	Edgar Link	pending
alxo-20221231.htm	Edgar Link	pending
alxo-20221231.xsd	Edgar Link	pending
alxo-ex10_11.htm	Edgar Link	pending
alxo-ex21_1.htm	Edgar Link	pending
alxo-ex23_1.htm	Edgar Link	pending
alxo-ex31_1.htm	Edgar Link	pending
alxo-ex31_2.htm	Edgar Link	pending
alxo-ex32_1.htm	Edgar Link	pending
alxo-ex32_2.htm	Edgar Link	pending
alxo-ex4_3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img49963848_0.jpg	Edgar Link	pending
img49963848_1.jpg	Edgar Link	pending
img49963848_10.jpg	Edgar Link	pending
img49963848_11.jpg	Edgar Link	pending
img49963848_12.jpg	Edgar Link	pending
alxo-20221231_cal.xml	Edgar Link	unprocessable
alxo-20221231_def.xml	Edgar Link	unprocessable
alxo-20221231_lab.xml	Edgar Link	unprocessable
alxo-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
alxo-20221231_htm.xml	Edgar Link	completed
img49963848_13.jpg	Edgar Link	pending
img49963848_14.jpg	Edgar Link	pending
img49963848_15.jpg	Edgar Link	pending
img49963848_16.jpg	Edgar Link	pending
img49963848_17.jpg	Edgar Link	pending
img49963848_18.jpg	Edgar Link	pending
img49963848_19.jpg	Edgar Link	pending
img49963848_2.jpg	Edgar Link	pending
img49963848_20.jpg	Edgar Link	pending
img49963848_21.jpg	Edgar Link	pending
img49963848_3.jpg	Edgar Link	pending
img49963848_4.jpg	Edgar Link	pending
img49963848_5.jpg	Edgar Link	pending
img49963848_6.jpg	Edgar Link	pending
img49963848_7.jpg	Edgar Link	pending
img49963848_8.jpg	Edgar Link	pending
img49963848_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

2023 Q1 Form 10-K Financial Statement

#000095017023007013 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO ALX ONCOLOGY HOLDINGS INC Stock $alxo

2023 Q1 Form 10-K Financial Statement

#000095017023007013 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo